» Articles » PMID: 31161221

Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine MiRNA Transcriptome

Abstract

Background: The development of noninvasive tests for the early detection of aggressive prostate tumors is a major unmet clinical need. miRNAs are promising noninvasive biomarkers: they play essential roles in tumorigenesis, are stable under diverse analytical conditions, and can be detected in body fluids.

Methods: We measured the longitudinal stability of 673 miRNAs by collecting serial urine samples from 10 patients with localized prostate cancer. We then measured temporally stable miRNAs in an independent training cohort (n = 99) and created a biomarker predictive of Gleason grade using machine-learning techniques. Finally, we validated this biomarker in an independent validation cohort (n = 40).

Results: We found that each individual has a specific urine miRNA fingerprint. These fingerprints are temporally stable and associated with specific biological functions. We identified seven miRNAs that were stable over time within individual patients and integrated them with machine-learning techniques to create a novel biomarker for prostate cancer that overcomes interindividual variability. Our urine biomarker robustly identified high-risk patients and achieved similar accuracy as tissue-based prognostic markers (area under the receiver operating characteristic = 0.72, 95% confidence interval = 0.69 to 0.76 in the training cohort, and area under the receiver operating characteristic curve = 0.74, 95% confidence interval = 0.55 to 0.92 in the validation cohort).

Conclusions: These data highlight the importance of quantifying intra- and intertumoral heterogeneity in biomarker development. This noninvasive biomarker may usefully supplement invasive or expensive radiologic- and tissue-based assays.

Citing Articles

Long non-coding RNA HOXC-AS1 promotes the malignancy by sponging miR-195-5p with ANLN in esophageal cancer.

Su Y, Kuang F, Guo H, Chen Q, Lai Y, Jing R Cytotechnology. 2025; 77(2):68.

PMID: 40012926 PMC: 11850670. DOI: 10.1007/s10616-025-00711-z.


Recent progress in microRNA research for prostate cancer.

Yuan F, Hu Y, Lei Y, Jin L Discov Oncol. 2024; 15(1):480.

PMID: 39331237 PMC: 11436510. DOI: 10.1007/s12672-024-01376-4.


Prostate cancer reshapes the secreted and extracellular vesicle urinary proteomes.

Khoo A, Govindarajan M, Qiu Z, Liu L, Ignatchenko V, Waas M Nat Commun. 2024; 15(1):5069.

PMID: 38871730 PMC: 11176296. DOI: 10.1038/s41467-024-49424-5.


Prediction of prostate cancer aggressiveness using magnetic resonance imaging radiomics: a dual-center study.

Pan N, Shi L, He D, Zhao J, Xiong L, Ma L Discov Oncol. 2024; 15(1):122.

PMID: 38625419 PMC: 11019191. DOI: 10.1007/s12672-024-00980-8.


NEAT1 promotes the progression of prostate cancer by targeting the miR-582-5p/EZH2 regulatory axis.

Xu W, Wu Y, Zhang G Cytotechnology. 2024; 76(2):231-246.

PMID: 38495291 PMC: 10940559. DOI: 10.1007/s10616-023-00612-z.


References
1.
Cornu J, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O . Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Prostate. 2012; 73(3):242-9. DOI: 10.1002/pros.22563. View

2.
Hausser J, Zavolan M . Identification and consequences of miRNA-target interactions--beyond repression of gene expression. Nat Rev Genet. 2014; 15(9):599-612. DOI: 10.1038/nrg3765. View

3.
Hagen R, Adamo P, Karamat S, Oxley J, Aning J, Gillatt D . Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence. Am J Clin Pathol. 2014; 142(4):533-40. DOI: 10.1309/AJCPH88QHXARISUP. View

4.
Javle M, Li Y, Tan D, Dong X, Chang P, Kar S . Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer. PLoS One. 2014; 9(1):e85942. PMC: 3896410. DOI: 10.1371/journal.pone.0085942. View

5.
Danila D, Heller G, Gignac G, Gonzalez-Espinoza R, Anand A, Tanaka E . Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007; 13(23):7053-8. DOI: 10.1158/1078-0432.CCR-07-1506. View